The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Colchicine in Acute Myocardial Infarction
Open accessAbstract
BACKGROUND: Inflammation is associated with adverse cardiovascular events. Data from recent trials suggest that colchicine reduces the risk of cardiovascular events. METHODS: In this multicenter trial with a 2-by-2 factorial design, we randomly assigned patients who had myocardial infarction to receive either colchicine or placebo and either spironolactone or placebo. The results of the colchicine trial are reported here. The primary efficacy outcome was a composite of death from cardiovascular causes, recurrent myocardial infarction, stroke, or unplanned ischemia-driven coronary revascularization, evaluated in a time-to-event analysis. C-reactive protein was measured at 3 months in a subgroup of patients, and safety was also assessed. RESULTS: A total of 7062 patients at 104 centers in 14 countries underwent randomization; at the time of analysis, the vital status was unknown for 45 patients (0.6%), and this information was most likely missing at random. A primary-outcome event occurred in 322 of 3528 patients (9.1%) in the colchicine group and 327 of 3534 patients (9.3%) in the placebo group over a median follow-up period of 3 years (hazard ratio, 0.99; 95% confidence interval [CI], 0.85 to 1.16; P = 0.93). The incidence of individual components of the primary outcome appeared to be similar in the two groups. The least-squares mean difference in C-reactive protein levels between the colchicine group and the placebo group at 3 months, adjusted according to the baseline values, was -1.28 mg per liter (95% CI, -1.81 to -0.75). Diarrhea occurred in a higher percentage of patients with colchicine than with placebo (10.2% vs. 6.6%; P<0.001), but the incidence of serious infections did not differ between groups. CONCLUSIONS: Among patients who had myocardial infarction, treatment with colchicine, when started soon after myocardial infarction and continued for a median of 3 years, did not reduce the incidence of the composite primary outcome (death from cardiovascular causes, recurrent myocardial infarction, stroke, or unplanned ischemia-driven coronary revascularization). (Funded by the Canadian Institutes of Health Research and others; CLEAR ClinicalTrials.gov number, NCT03048825.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Self-citationEfficacy and safety of low-dose colchicine after myocardial infarction
Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1912388 · Cited by 3,159
2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C., Andreotti, F., Koskinas, K. C., Rossello, X., Adamo, M., Ainslie, J., Banning, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 2,774
Self-citationColchicine in Patients with Chronic Coronary Disease
Nidorf, S. M., Fiolet, A. T. L., Mosterd, A., Eikelboom, J. W., Schut, A., Opstal, T. S. J., The, S. H. K., Xu, X.-F., Ireland, M. A., Lenderink, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021372 · Cited by 2,299
Self-citationColchicine—Update on mechanisms of action and therapeutic uses
Leung, Y. Y., Yao Hui, L. L., & Kraus, V. B. (2015) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2015.06.013 · Cited by 950
Fiolet, A. T. L., Opstal, T. S. J., Mosterd, A., Eikelboom, J. W., Jolly, S. S., Keech, A. C., Kelly, P., Tong, D. C., Layland, J., Nidorf, S. M., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab115 · Cited by 253
Self-citationJolly, S. S., Cairns, J. A., Yusuf, S., Rokoss, M. J., Gao, P., Meeks, B., Kedev, S., Stankovic, G., Moreno, R., Gershlick, A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00448-1 · Cited by 222
Self-citationKelly, P. J., Lemmens, R., Weimar, C., Walsh, C., Purroy, F. F., Barber, M., Collins, R., Cronin, S., Członkowska, A., Desfontaines, P., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00968-1 · Cited by 180
Li, J., Meng, X., Shi, F., Jing, J., Gu, H., Jin, A., Jiang, Y., Li, H., Johnston, S. C., Hankey, G. J., et al. (2024) · BMJ · doi:10.1136/bmj-2023-079061 · Cited by 123
C-Reactive-Protein-Associated Increase in Myocardial Infarct Size After Ischemia/Reperfusion
Barrett, T. D., Hennan, J. K., Marks, R. M., & Lucchesi, B. R. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.040600 · Cited by 90
Routine Spironolactone in Acute Myocardial Infarction
Jolly, S. S., d’Entremont, M.-A., Pitt, B., Lee, S. F., Mian, R. I., Tyrwhitt, J., Kedev, S., Montalescot, G., Cornel, J. H., Stankovic, G. R., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2405923 · Cited by 54
Self-citationd’Entremont, M.-A., Lee, S. F., Mian, R. I., Kedev, S., Montalescot, G., Cornel, J. H., Stankovic, G. R., Moreno, R., Storey, R. F., Henry, T. D., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.06.007 · Cited by 41
Self-citationRandomized Trials Stopped Early for Benefit: A Systematic Review
Montori, V. M., Devereaux, P. J., Adhikari, N. K. J., Burns, K. E. A., Eggert, C. H., Briel, M., Lacchetti, C., Leung, T. W., Darling, E., Bryant, D. M., et al. (2005) · JAMA · doi:10.1001/jama.294.17.2203 · Cited by 26
Self-citation
Cited by
Roadmap for alleviating the manifestations of ageing in the cardiovascular system
Liberale, L., Tual-Chalot, S., Sedej, S., Ministrini, S., Georgiopoulos, G., Grunewald, M., Bäck, M., Bochaton-Piallat, M.-L., Boon, R. A., Ramos, G. C., et al. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01130-5 · Cited by 59
“…in 2024 sparked debate because colchicine treatment did not reduce the incidence of cardiovascular events in patients with myocardial infarction 279 , whereas a meta-analysis of six randomized clinical trials involving nearly 15,000 patients with previous coronary disease showed a consistent…”
Metadata
- Authors
- Jolly, S. S., d’Entremont, M.-A., Lee, S. F., Mian, R., Tyrwhitt, J., Kedev, S., Montalescot, G., Cornel, J. H., Stanković, G., Moreno, R., Storey, R. F., Henry, T. D., Mehta, S. R., Bossard, M., Kala, P., Layland, J., Zafirovska, B., Devereaux, P. J., Eikelboom, J., Cairns, J. A., Shah, B., Sheth, T., Sharma, S. K., Tarhuni, W., Conen, D., Tawadros, S., Lavi, S., & Yusuf, S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-02-13
- Volume
- 392
- Issue
- 7
- Pages
- 633-642
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4404448964
- Cited by
- 332
- References
- 13
- FWCI
- 89.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.